Aptose Announces Executive Management Changes

0
126

─ Appoints Philippe Ledru as Chief Commercial Officer ─

─ Announces resignation of CFO/CBO Jotin Marango, MD, PhD ─

SAN DIEGO and TORONTO, April 07, 2022 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ:APTO, TSX:APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced the appointment of Mr. Philippe Ledru to the position of Chief Commercial Officer. In this role, Mr. Ledru is responsible for providing executive leadership and vision for commercial development and marketing strategies for the future commercial launches of Aptose's innovative oncology medicines and to consolidate responsibilities over business development and licensing.

“Philippe's broad knowledge with marketing of oncology products and specific experience in hematology, branding and early commercial strategy will serve Aptose well during this next phase of development for our lead myeloid kinome inhibitor HM43239 and beyond for luxeptinib,” said William G. Rice, Ph.D., Chairman, President and Chief Executive Officer. “We're delighted to have him join our executive management team.”

Mr. Ledru brings to Aptose more than 30 years of pharmaceutical industry experience in the U.S. and Europe, including innovative drug development and commercial and strategic experience at two top global oncology companies. Most recently, he served as Associate Vice President and Head of Oncology New Products at Merck & Co, where he was responsible for commercial leadership over the entire Merck oncology pipeline, over 25 assets from discovery to mid-stage clinical development, across major solid tumors and hematological malignancies. At Merck, he also provided leadership on all licensing and M&A activities, including the Peloton Therapeutics and Arqule acquisitions in 2019. Prior, Mr. Ledru spent a 20+ year career at Novartis in the U.S. and France, most recently as Senior Director of Early Commercial Strategy focused on oncology products. There he also was part of the brand team and had early commercial development and global marketing responsibilities for several new compounds, including midostaurin. Earlier at Novartis Oncologie, he helped lead launches of several oncology products, including imatinib …

Full story available on Benzinga.com

LEAVE A REPLY

Please enter your comment!
Please enter your name here